Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers
This article was originally published in The Tan Sheet
Executive Summary
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.
You may also be interested in...
FDA Examination Of Homeopathic Regulation Looks Beyond Safety History
CDER Director Janet Woodcock says the current regulatory framework limits FDA’s direct regulation of homeopathics to post-market surveillance. During a two-day public hearing, agency officials question stakeholders about trials, labeling and how well consumers understand their products.
Zicam Case Shows FDA Takes Defining Adverse Events Seriously
Narrowly interpreting the definition of serious adverse events - compared to FDA's approach - is already costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products
GNC, Rite Aid expansion plans
GNC and Rite Aid announce Aug. 7 an agreement that will nearly double the number of GNC LiveWell locations within Rite Aid stores nationwide by 2014. Under the contract, the firms expect 1,125 GNC locations to be added to the 1,300 currently operating inside Rite Aid stores; the agreement also provides Rite Aid with an option to extend the contract through 2019 and open 250 more stores during that time period. Rite Aid plans to add "several hundred" GNC store-within-Rite Aid store locations during its fiscal year, ending March 1, 2008...